Our current data is in close consistency with recent findings of Wu S with co-authors, illustrating a high potency of erdafitinib, a small-molecule pan-FGFR kinase inhibitor to induce sensitization of ABCB1-overexpressing cancer cell lines to certain chemotherapeutic drugs, including PTX, vincristine, and topotecan [102]. This evidence concerns the gene ABCB1 and cancer.